Vedolizumab as a Potential Culprit in the Development of Ovarian Teratoma?
Vedolizumab is a new humanized monoclonal antibody that has been reserved for those with moderate-to-severe Crohn’s disease and ulcerative colitis who have failed immunomodulator and TNF-α antagonist therapy, and for those who have an increased risk for developing progressive multifocal leukoencepha...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Karger Publishers
2017-12-01
|
| Series: | Case Reports in Gastroenterology |
| Subjects: | |
| Online Access: | https://www.karger.com/Article/FullText/484199 |